The arrival of biosimilars is helping expand access to medicines for patients, health care providers and policymakers across Canada. These drugs represent an enormous opportunity to not only enhance patient care but also improve the sustainability of Canadian health care.
B.C.’s Approach to Biosimilars Can Improve Patient Care
The Government of British Columbia is building on the momentum of the Biosimilars Initiative, recently announcing Phase 2 of a process to implement a one-time transition of patients currently using a reference biologic to a biosimilar in consultation with their doctors. Through this policy change, the Government of B.C. is expanding treatment options for patients and their physicians across the province. Learn more
What are Biosimilars?
Biosimilars are biologic medicines that have been approved by Health Canada after a rigorous and evidence-based review process. Health Canada requires every biosimilar to demonstrate its similarity to another biologic medicine that is already available in the Canadian marketplace and no longer protected by a patent.
As Health Canada states, “you can have the same confidence in the quality, efficacy and safety of a biosimilar as in any other biologic drug.”
The Canadian Biosimilars Forum
The Canadian Biosimilars Forum is an alliance of companies who represent the breadth of the biosimilars industry and who are collectively working to increase awareness, access and adoption of biosimilars across Canada. Learn more about the Forum
Biosimilars can play a significant role in the health care system.